肾移植患者MRP2C3972T基因多态性对吗替麦考酚酯药动学参数、不良反应及急性排斥反应的影响

目的：研究MRP2 C3972T基因突变对肾移植术后患者服用吗替麦考酚酯药动学参数.不良反应及急性排斥反应的影响.方法：采用聚合酶链反应（PCR）和限制性内切片段长度多态性（RFLP）方法检测肾移植患者MRP2 C3972T基因型,比较不同基因型患者之间吗替麦考酚酯的药动学参数.不良反应及急性排斥反应发生率的差异.结果：肾移植术后第7天.第14天.第30天各基因型患者在C0、C0/D、AUC0-12、AUC0-12/D等值上没有显著性差异,但突变型患者（C/C＋T/T）在术后第7天、第14天、第30天的C0/D、AUC0-12/D均低于野生型（C/C）患者.三组间不良反应及急性排斥反应发生率没有显著差异.结论：MRP2C3972T突变可以在一定程度上降低血浆中麦考酚酸的浓度.

Effect of MRP2 C3972T genetic polymorphism on pharmacokinetics, adverse reactions and acute rejection of mycophenolate mofetil in patients kidney transplantation

Objective： To study the pharmacokinetics, adverse effects and acute rejection of patients who were administrated with mycophenolate mofetil after renal transplantation with MRP2 C3972T gene mutation. Methods： The MRP2 C3972T genotype was determined by PCR-RFLP method. The differences ofpharmacokinetic parameters, adverse reactions and acute rejection were compared among all of the genotype groups treated with mycophenolate mofetil, Results： There were no significant difference in Co, C0/D, AUC0-12, AUC0-12/D among different genotypes on the 7th, 14th and 30th day after renal transplantation, but patients with mutation （C/C＋T/T） had the lower C0/D, AUC0-12/D on the 7th, 14th and 30th day than the wide type. The incidence of adverse reactions and acute rejection in the three groups were not significantly different. Conclusion： The plasma levels of mycophenolic acid could be reduced to a certain extent on this mutation.